Baek-Nam Kim

Baek-Nam Kim

Auto-generated profile, based on publicly available information

Baek-Nam Kim

Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BKBaek-Nam Kim
Baek-Nam Kim
APAnton Peleg
Anton Peleg
TLThomas P Lodise
Thomas P Lodise
Jeffrey LipmanJeffrey Lipman
Jeffrey Lipman
JLJian Li
Jian Li
DPDavid L Paterson
David L Paterson

1 January 2018 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
CKCheol-In Kang
Cheol-In Kang
JKJieun Kim
Jieun Kim
DPDae Won Park
Dae Won Park
BKBaek-Nam Kim
Baek-Nam Kim
UHU-Syn Ha
U-Syn Ha
SWSeong-Heon Wie
Seong-Heon Wie
Kang CI, et al. Infect Chemother. 2018 Mar;50(1):67-100. https://doi.org/10.3947/ic.2018.50.1.67

19 July 2017 in Thorax
Verified
Journal Article
Open access
PDF file
KHKi-Ho Hong
Ki-Ho Hong
JCJae-Phil Choi
Jae-Phil Choi
SHSeon-Hui Hong
Seon-Hui Hong
JLJeewon Lee
Jeewon Lee
JKJi-Soo Kwon
Ji-Soo Kwon
SKSung-Han Kim
Sung-Han Kim
We evaluated the clinical characteristics, cytokine/chemokine concentrations, viral shedding and antibody kinetics in 30 patients with Middle East respiratory syndrome (MERS), including 6 non-survivors admitted to 3 MERS-designated hospitals. Old age, low albumin, altered mentality and high pneumonia severity index score at admission were risk factors for mortality. In addition, severe signs of inflammation at initial presentation (at hospital days 1-4), such as high inducible protein-10 (p=0.0013), monocyte chemoattractant protein-1 (p=0.0007) and interleukin 6 (p=0.0007) concentrations, and poor viral control (high viral load at hospital days 5–10, p<0.001) without adequate antibody titres (low antibody titre at hospital days 11–16, p=0.07) during the course of disease, were associated with mortality.

1 January 2016 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
WCWon Suk Choi
Won Suk Choi
CKCheol-In Kang
Cheol-In Kang
YKYonjae Kim
Yonjae Kim
JCJae-Phil Choi
Jae-Phil Choi
JJJoon Sung Joh
Joon Sung Joh
TDThe Korean Society Of Infectious Diseases
The Korean Society Of Infectious Diseases
Choi WS, et al. Infect Chemother. 2016 Jun;48(2):118-126. https://doi.org/10.3947/ic.2016.48.2.118

1 February 2003 in Scandinavian Journal of Infectious Diseases
Verified
Journal Article
Closed access
BKBaek-Nam Kim
Baek-Nam Kim
NKNam Joong Kim
Nam Joong Kim
MKMi-Na Kim
Mi-Na Kim
YKYang Soo Kim
Yang Soo Kim
JWJun-Hee Woo
Jun-Hee Woo
JRJiso Ryu
Jiso Ryu
To characterize the clinical features of bacteraemia due to tribe Proteeae, 132 cases among 130 patients from 1991 to 2000 were analysed. The organisms included the Proteus species in 63 cases (P. mirabilis in 41, P. penneri in 2 and P. vulgaris in 20), the Providencia species in 8 (P. rettgeri in 3 and P. stuartii 5) and Morganella morganii in 61. Morganella bacteraemia occurred more frequently in the hospital (70.5%). Biliary and hepatic diseases were predominant in cases with Morganella bacteraemia while cardiovascular, urological and neurological diseases were more common in cases with Proteus bacteraemia. Biliary drainage catheters had more frequently been placed in cases with Morganella bacteraemia (39.3%, p < 0.001), and urinary catheters more frequently in cases with Proteus bacteraemia (17.5%). Biliary infection was most common in cases with Morganella bacteraemia (49.2%), while urinary tract infection (UTI) was most common in cases with Proteus bacteraemia (47.6%). Mortality directly related to bacteraemia due to tribe Proteeae was 20.8% (22.6, 50.0 and 15.0% for Proteus, Providencia and Morganella bacteraemia, respectively). In conclusion, Morganella bacteraemia was most frequently associated with biliary infection, while Proteus bacteraemia was most frequently with UTI. Providencia bacteraemia was relatively uncommon and it can be associated with infections other than UTI.

2 December 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
JKJi-Soo Kwon
Ji-Soo Kwon
JKJi Yeun Kim
Ji Yeun Kim
MKMin-Chul Kim
Min-Chul Kim
SPSe Yoon Park
Se Yoon Park
BKBaek-Nam Kim
Baek-Nam Kim
SKSung-Han Kim
Sung-Han Kim
The severity of COVID-19 ranges from mild to critical diseases. However, limited data have been published on the detailed kinetics of viral load and host immune response throughout the disease course depending on disease severity. In this study, we comprehensively analyzed viral load, antibody responses to SARS-CoV-2, and cytokines/chemokines during the disease course, and identified the factors related to severity. Nasopharyngeal (NP) and plasma specimens were obtained from 31 patients with COVID-19 during hospitalization. Viral RNA in NP specimens was quantified by reverse transcription–PCR. Anti–SARS-CoV-2 antibodies and cytokines/chemokines in plasma specimens were analyzed by ELISA and cytometric bead array. The viral load in patients with COVID-19 peaked at the early stage of the disease and continuously decreased. Severe and critical cases showed higher viral load and prolonged viral shedding than asymptomatic and mild cases. Whereas plasma IgG was gradually increased and maintained during hospitalization, plasma IgM peaked at 3 weeks after symptom onset and dissipated. The antibody response in severe and critical cases was slightly delayed but stronger than those in others. High levels of interferon (IFN)-α, IFN-γ–induced protein-10, monokine induced by IFN-γ, and interleukin-6 at 5–10 days from symptom onset were associated with the severity of COVID-19. Our data indicate that high viral load in the respiratory tract and excessive production of cytokines and chemokines between 1 and 2 weeks from the symptom onset were significantly associated with the severity of COVID-19.